# Johanna A Kremer Hovinga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3018108/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 156 papers | 8,340 citations | 41344 49 h-index | 48315 88 g-index |
| 162 all docs | 162 docs citations | 162 times ranked | 5467 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Advances, 2022, 6, 993-997. | 5.2 | 14 |
| 2 | Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARSâ€CoVâ€2 vaccination. European Journal of Neurology, 2022, 29, 339-344. | 3.3 | 38 |
| 3 | Abstract 51: Age Stratified Risk Of Cerebral Venous Sinus Thrombosis After Sars-Cov-2 Vaccination. Stroke, 2022, 53, . | 2.0 | 0 |
| 4 | Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood, 2022, 139, 2720-2724. | 1.4 | 16 |
| 5 | Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology, 2022, 98, . | 1.1 | 19 |
| 6 | Cerebral Venous Sinus Thrombosis Associated with Vaccine-Induced Thrombotic Thrombocytopeniaâ€”A Narrative Review. Clinical and Translational Neuroscience, 2022, 6, 11. | 0.9 | 0 |
| 7 | Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature. Frontiers in Medicine, 2022, 9, . | 2.6 | 3 |
| 8 | Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789. | 1.4 | 4 |
| 9 | Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Journal of Immunology, 2022, 208, 2497-2507. | 0.8 | 1 |
| 10 | Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp>â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573. | 5.3 | 21 |
| 11 | COVIDâ€19 patients often show highâ€titer nonâ€plateletâ€activating antiâ€PF4/heparin IgG antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1294-1298. | 3.8 | 62 |
| 12 | Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141. | 5.2 | 39 |
| 13 | Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861. | 1.4 | 103 |
| 14 | SantÃ© psychique lors de maladies chroniques Ã  lâ€™exemple de lâ€™hÃ©mophilie. Paediatrica, 2021, 32, . | 0.0 | 0 |
| 15 | The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601. | 2.7 | 3 |
| 16 | Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood, 2021, 137, 3563-3575. | 1.4 | 31 |
| 17 | Psychische Gesundheit bei chronischen Erkrankungen am Beispiel der HÃmophilie. Paediatrica, 2021, 32, . | 0.1 | 0 |
| 18 | Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 332. | 7.4 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Postâ€SARSâ€CoVâ€2â€vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. European Journal of Neurology, 2021, 28, 3656-3662. | 3.3 | 84 |
| 20 | Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccineâ€"Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314. | 9.0 | 89 |
| 21 | EHA Endorsement of the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. HemaSphere, 2021, 5, e647. | 2.7 | 2 |
| 22 | Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484. | 3.8 | 45 |
| 23 | Hypertension in patients with hereditary thrombotic thrombocytopenic purpura. EJHaem, 2020, 1, 342-343. | 1.0 | 4 |
| 24 | Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland. Hamostaseologie, 2020, 40, S5-S14. | 1.9 | 5 |
| 25 | Acquired hemophilia A and plasma cell neoplasms: aÂcase report and review of theÂliterature. Journal of Medical Case Reports, 2020, 14, 206. | 0.8 | 4 |
| 26 | Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence. Journal of Thrombosis and Haemostasis, 2020, 18, 1598-1617. | 3.8 | 23 |
| 27 | Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210. | 1.6 | 9 |
| 28 | Evidence-Based Minireview: Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2020, 2020, 82-84. | 2.5 | 0 |
| 29 | Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Medical Weekly, 2020, 150, w20422. | 1.6 | 15 |
| 30 | Obinutuzumab in two patients suffering from immuneâ€mediated thrombotic thrombocytopenic purpura intolerant to rituximab. American Journal of Hematology, 2019, 94, E259-E261. | 4.1 | 11 |
| 31 | Hereditary Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 381, 1653-1662. | 27.0 | 93 |
| 32 | Estimation of Nuwiq Â® (simoctocog alfa) activity using oneâ€stage and chromogenic assaysâ€"Results from an international comparative field study. Haemophilia, 2019, 25, 708-717. | 2.1 | 7 |
| 33 | The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115. | 3.5 | 99 |
| 34 | Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome. Blood Advances, 2019, 3, 2664-2667. | 5.2 | 0 |
| 35 | Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences, 2019, 20, 5963. | 4.1 | 6 |
| 36 | Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl. Hamostaseologie, 2019, 39, 404-408. | 1.9 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346. | 27.0 | 625 |
| 38 | Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366. | 1.4 | 2 |
| 39 | Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 618-629. | 3.8 | 41 |
| 40 | Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood, 2018, 131, 1360-1371. | 1.4 | 57 |
| 41 | Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373. | 1.4 | 2 |
| 42 | Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739. | 1.4 | 3 |
| 43 | Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744. | 1.4 | 3 |
| 44 | Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142. | 1.4 | 3 |
| 45 | Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature. Blood, 2018, 132, 2496-2496. | 1.4 | 0 |
| 46 | Description of the First Cases with ADAMTS13 Mutations in Hungary. Blood, 2018, 132, 5003-5003. | 1.4 | 0 |
| 47 | Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2017, 15, 1448-1452. | 3.8 | 94 |
| 48 | Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers, 2017, 3, 17020. | 30.5 | 242 |
| 49 | Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. , 2017, , 851-871. | | 1 |
| 50 | Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%â€20%. American Journal of Hematology, 2017, 92, E644-E646. | 4.1 | 20 |
| 51 | Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood, 2017, 130, 2055-2063. | 1.4 | 191 |
| 52 | Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney International Reports, 2017, 2, 1088-1095. | 0.8 | 9 |
| 53 | Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322. | 3.8 | 362 |
| 54 | Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600. | 5.2 | 207 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Progress in Haemostasis. From individual patients to pathophysiological insights. Hamostaseologie, 2017, 37, 9-11. | 1.9 | 0 |
| 56 | Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178. | 1.4 | 68 |
| 57 | Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679. | 0.8 | 25 |
| 58 | High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. Journal of Thrombosis and Haemostasis, 2016, 14, 73-82. | 3.8 | 49 |
| 59 | Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. Blood, 2016, 127, 2934-2936. | 1.4 | 13 |
| 60 | Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094. | 1.4 | 99 |
| 61 | Thromboembolism in patients with congenital afibrinogenaemia. Thrombosis and Haemostasis, 2016, 116, 722-732. | 3.4 | 32 |
| 62 | Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 511-522. | 27.0 | 480 |
| 63 | Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. International Journal of Hematology, 2016, 103, 283-291. | 1.6 | 20 |
| 64 | Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS)). Blood, 2016, 128, 135-135. | 1.4 | 4 |
| 65 | Blocking Protein S Improves Hemostasis in Hemophilia a and B. Blood, 2016, 128, 79-79. | 1.4 | 1 |
| 66 | Successful liver transplantation in a child with acuteâ€onâ€chronic liver failure and acquired thrombotic thrombocytopenic purpura. Liver Transplantation, 2015, 21, 704-706. | 2.4 | 1 |
| 67 | Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 1151-1153. | 3.8 | 37 |
| 68 | Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. Thrombosis Research, 2015, 135, S30-S33. | 1.7 | 32 |
| 69 | ADAMTS13 gene variants and function in women with preeclampsia: A population- based nested case-control study from the HUNT Study. Thrombosis Research, 2015, 136, 282-288. | 1.7 | 7 |
| 70 | Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, E22. | 4.1 | 13 |
| 71 | Impaired DNase1â€mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2015, 13, 732-742. | 3.8 | 109 |
| 72 | Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614. | 2.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura. Hamostaseologie, 2014, 34, 244-248. | 1.9 | 6 |
| 74 | The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thrombosis and Haemostasis, 2014, 111, 1180-1183. | 3.4 | 23 |
| 75 | Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the <scp>ADAMTS</scp>13 gene. European Journal of Haematology, 2014, 92, 168-171. | 2.2 | 10 |
| 76 | Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680. | 1.4 | 61 |
| 77 | Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2014, 99, 779-787. | 3.5 | 51 |
| 78 | The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood, 2014, 124, 3469-3479. | 1.4 | 40 |
| 79 | Plasma DNA is elevated in patients with deep vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 341-348.e1. | 1.6 | 99 |
| 80 | Novel ADAMTS13 mutations in an obstetric patient with Upshawâ€šchulman syndrome. Journal of Clinical Apheresis, 2013, 28, 311-316. | 1.3 | 8 |
| 81 | Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682. | 1.5 | 193 |
| 82 | Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029. | 1.4 | 161 |
| 83 | Designed Ankyrin Repeat Proteins: A New Approach to Mimic Complex Antigens for Diagnostic Purposes?. PLoS ONE, 2013, 8, e60688. | 2.5 | 6 |
| 84 | Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie, 2013, 33, 138-143. | 1.9 | 43 |
| 85 | Acquired thrombotic thrombocytopenic purpura. Hamostaseologie, 2013, 33, 121-130. | 1.9 | 19 |
| 86 | Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303. | 3.5 | 69 |
| 87 | Improving on nature: redesigning ADAMTS13. Blood, 2012, 119, 3654-3655. | 1.4 | 7 |
| 88 | Indications for a protective function of beta2â€glycoprotein <scp>I</scp> in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2012, 159, 94-103. | 2.5 | 5 |
| 89 | Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188. | 1.9 | 35 |
| 90 | Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood, 2012, 120, 1157-1164. | 1.4 | 249 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532. | 1.6 | 63 |
| 92 | Initial experience from a doubleâ€blind, placeboâ€controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2012, 87, 430-432. | 4.1 | 71 |
| 93 | Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-6. | 2.5 | 21 |
| 94 | Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-616. | 2.5 | 58 |
| 95 | Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 366-366. | 1.4 | 8 |
| 96 | Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 362-362. | 1.4 | 1 |
| 97 | Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation. Thrombosis and Haemostasis, 2011, 106, 381-382. | 3.4 | 5 |
| 98 | Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243. | 1.6 | 27 |
| 99 | Recombinant ADAMTS13 normalizes von Willebrand factorâ€cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of Thrombosis and Haemostasis, 2011, 9, 936-944. | 3.8 | 106 |
| 100 | Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2011, 9, 1285-1291. | 3.8 | 34 |
| 101 | Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511. | 1.4 | 477 |
| 102 | Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847. | 4.1 | 75 |
| 103 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2010, 116, 726-726. | 1.4 | 4 |
| 104 | Komplexe GerinnungsstÃ¶rungen. , 2010, , 529-569. | | 0 |
| 105 | Circulating Nucleosomes Reflect Disease Activity in Patients with Thrombotic Microangiopathies.. Blood, 2010, 116, 1437-1437. | 1.4 | 0 |
| 106 | Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137. | 5.8 | 48 |
| 107 | Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887. | 1.6 | 99 |
| 108 | Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101. | 1.6 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | VH1â€69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2009, 7, 421-428. | 3.8 | 59 |
| 110 | IgG subclass distribution of antiâ€ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2009, 7, 1703-1710. | 3.8 | 170 |
| 111 | A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Annals of Hematology, 2008, 87, 663-666. | 1.8 | 23 |
| 112 | Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541. | 3.8 | 57 |
| 113 | Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707. | 2.5 | 50 |
| 114 | The Oklahoma Thrombotic Thrombocytopenic Purpuraâ€“Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286. | 2.2 | 40 |
| 115 | Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica, 2008, 93, 172-177. | 3.5 | 44 |
| 116 | Current management of thrombotic thrombocytopenic purpura. Current Opinion in Hematology, 2008, 15, 445-450. | 2.5 | 39 |
| 117 | Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura â€“ Towards a Phenotype-Genotype Correlation?. Blood, 2008, 112, 274-274. | 1.4 | 9 |
| 118 | Acute pancreatitis and thrombotic thrombocytopenic purpura. European Journal of Medical Research, 2008, 13, 481-2. | 2.2 | 7 |
| 119 | Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica, 2007, 92, 936-943. | 3.5 | 75 |
| 120 | Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2007, 5, 866-867. | 3.8 | 72 |
| 121 | ADAMTSâ€13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of Thrombosis and Haemostasis, 2007, 5, 2284-2290. | 3.8 | 153 |
| 122 | Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311. | 1.4 | 3 |
| 123 | The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. Blood, 2007, 110, 277-277. | 1.4 | 6 |
| 124 | Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317. | 1.4 | 2 |
| 125 | Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.. Blood, 2007, 110, 278-278. | 1.4 | 19 |
| 126 | Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thrombosis and Haemostasis, 2006, 95, 212-220. | 3.4 | 86 |
| 128 | A common origin of the 4143insA ADAMTS13 mutation. Thrombosis and Haemostasis, 2006, 96, 3-6. | 3.4 | 74 |
| 129 | Treatment of thrombotic thrombocytopenic purpura. Vox Sanguinis, 2006, 90, 245-254. | 1.5 | 57 |
| 130 | Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. Journal of Thrombosis and Haemostasis, 2006, 4, 1146-1148. | 3.8 | 89 |
| 131 | Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2006, 4, 2355-2364. | 3.8 | 73 |
| 132 | A new tool to further explore the role of ADAMTS-13 in health and disease. Journal of Thrombosis and Haemostasis, 2006, 4, 952-954. | 3.8 | 2 |
| 133 | ADAMTS13 activity in sickle cell disease. American Journal of Hematology, 2006, 81, 492-498. | 4.1 | 54 |
| 134 | Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067. | 1.4 | 3 |
| 135 | Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 3953-3953. | 1.4 | 0 |
| 136 | Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood, 2005, 105, 542-544. | 1.4 | 152 |
| 137 | ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267. | 1.4 | 275 |
| 138 | Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2005, 3, 1663-1675. | 3.8 | 159 |
| 139 | Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?. Thrombosis and Haemostasis, 2005, 94, 1186-1189. | 3.4 | 12 |
| 140 | Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms. Clinical Chemistry, 2005, 51, 516-521. | 3.2 | 13 |
| 141 | Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?. Thrombosis and Haemostasis, 2005, 94, 1186-9. | 3.4 | 8 |
| 142 | Thrombotic thrombocytopenic purpura. The Hematology Journal, 2004, 5, S6-S11. | 1.4 | 4 |
| 143 | A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. Journal of Thrombosis and Haemostasis, 2004, 2, 54-57. | 3.8 | 43 |
| 144 | Soluble thrombomodulin in patients with established atherosclerosis. Journal of Thrombosis and Haemostasis, 2004, 2, 200-201. | 3.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Seminars in Hematology, 2004, 41, 75-82. | 3.4 | 79 |
| 146 | Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Seminars in Hematology, 2004, 41, 48-59. | 3.4 | 39 |
| 147 | Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood, 2004, 103, 4195-4197. | 1.4 | 61 |
| 148 | Factor V Leiden Is Not a Risk Factor for Thrombotic Microangiopathies without Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 850-850. | 1.4 | 0 |
| 149 | Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica, 2004, 89, 320-4. | 3.5 | 46 |
| 150 | The von Willebrand Factor-Cleaving Protease (ADAMTS-13) and the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP). Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 417-421. | 0.3 | 18 |
| 151 | Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 1141-1147. | 1.6 | 10 |
| 152 | Discrepant activity levels of von Willebrand factorâ€“cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. Blood, 2003, 102, 1148-1148. | 1.4 | 4 |
| 153 | Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2. Hamostaseologie, 2003, 23, 103-8. | 1.9 | 0 |
| 154 | Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Medical Weekly, 2003, 133, 325-32. | 1.6 | 29 |
| 155 | Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis, 2002, 161, 261-267. | 0.8 | 61 |
| 156 | IN VITRO EVALUATION OF THE EFFICACY AND BIOCOMPATIBILITY OF NEW, SYNTHETIC ABO IMMUNOABSORBENTS. Transplantation, 1995, 60, 425-429. | 1.0 | 32 |